- Abstract
- Core Tip
- Article Highlights
- Full Article (PDF)
- Full Article with Cover (PDF)
- Full Article (XML)
- Full Article (HTML)
- Audio
- PubMed Central
- PubMed
- CrossRef
- Google Scholar
- Similar Articles (374)
- Timeline of Article Publication (0)
- Authors Evaluation (2)
- Article Quality Tracking (2)
- Reader Comments (2)
- Reference Citation Analysis (2)
Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4103)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Aug 27, 2023 (publication date) through Jul 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Lai RM, Lin S, Wang MM, Li N, Zhou JH, Lin XY, Chen TB, Zhu YY, Zheng Q. Tenofovir alafenamide significantly increased serum lipid levels compared with entecavir therapy in chronic hepatitis B virus patients. World J Hepatol 2023; 15(8): 964-972 [PMID: 37701915 DOI: 10.4254/wjh.v15.i8.964] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v15/i8/964.htm |
| Number | Citing Articles |
| 1 |
Yu-Tong Sun, Qian-Qian Chen. Review on article of effects of tenofovir alafenamide and entecavir in chronic hepatitis B virus patients. World Journal of Hepatology 2024; 16(1): 109-111 doi: 10.4254/wjh.v16.i1.109
Abstract(167) |
Core Tip(181) |
Full Article(HTML)(580)
|
Full Article with Cover (PDF)-11079K(37)
|
Full Article (Word)-109K(11)
|
Audio-243K(0)
|
Peer-Review Report-215K(22)
|
Answering Reviewers-19K(21)
|
Full Article (PDF)-325K(47)
|
Full Article (XML)-24K(38)
|
Times Cited (0)
|
Total Visits (1542)
|
Open
|
| 2 |
Pin-Nan Cheng, Ming-Lung Yu. Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer. Clinical and Molecular Hepatology 2024; 30(2): 144 doi: 10.3350/cmh.2024.0115
|
| 3 |
Wenjuan Zhao, Yi Liu, Mengdi Zhang, Zixin Cui, Zhan Qu, Yiyang Li, Meijuan Wan, Wen Wang, Yunru Chen, Lei Shi, Jianzhou Li, Feng Ye. Lipid safety of tenofovir alafenamide during 96-week treatment in treatment-naive chronic hepatitis B patients. Frontiers in Medicine 2024; 11 doi: 10.3389/fmed.2024.1399665
|
| 4 |
Pin-Nan Cheng, Ming-Lung Yu. Reply to “Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in HBV patients”. Clinical and Molecular Hepatology 2024; doi: 10.3350/cmh.2024.0228
|
| 5 |
Danqing Hu, Peng Wang, Xiaojing Wang, Xue Hu, Da Huang, Weiming Yan, Dong Xi, Meifang Han, Qin Ning, Hongwu Wang. The efficacy of antiviral treatment in chronic hepatitis B patients with hepatic steatosis. Heliyon 2024; 10(7): e28653 doi: 10.1016/j.heliyon.2024.e28653
|